The Pharma Data

JANUARY 27, 2021

COVID-19 Antibody Treatments Exceed Expectations in Early Trials. 27, 2021 — Promising new data on two antibody cocktails suggest these therapies can keep COVID-19 patients out of the hospital and even prevent illness altogether in some people. Professional. WEDNESDAY, Jan. At the same time, Regeneron Pharmaceuticals Inc.

Antibody 52

Antibody Trials Regulation Drugs 52

The Pharma Data

AUGUST 20, 2020

Poor regulation of antibodies tests – that could indicate if someone has had coronavirus – could be putting the public at risk, doctors have warned. It is still not known whether having antibodies will protect people from a second infection. Coronavirus infection triggers the immune system to produce antibodies.

Antibody 52

Antibody Regulation Doctors Doctor 52

The Pharma Data

JANUARY 21, 2021

Eli Lilly reported yesterday that its monoclonal antibody bamlanivimab (LY-CoV555) significantly lessened the risk of contracting COVID-19 among nursing home residents and staff, according to findings from a phase 3 trial. James Miessler. Source link.

Antibody 52

Antibody Nurses Regulation Research 52

Drug Discovery World

JUNE 30, 2023

Whether it be a monoclonal antibody to treat peanut allergy, or using artificial intelligence (AI) to identify influenza drug targets, each discovery reflects the level of scientific innovation and diversity of approaches being employed in drug development today. The top stories: Could a monoclonal antibody treat peanut allergy?

Allergies 52

Allergies Drugs Antibody Regulation 52

Drug Discovery Today

APRIL 5, 2022

Researchers delve into the inner workings of the antibody immune response, finding key differences in the metabolism of two closely related immune cell subsets.

Immune Response 45

Immune Response Regulation Antibody Research 45

XTalks

DECEMBER 28, 2023

BillionToOne, a company specializing in molecular diagnostics, has partnered with Janssen Research & Development, LLC, a Johnson & Johnson division, to conduct the AZALEA Phase III clinical trial globally. Nipocalimab is an investigational monoclonal antibody that targets the neonatal Fc receptor.

Trials 97

Trials Clinical Trials Clinical Trials Antibody 97

BioPharma Reporter

JUNE 1, 2021

Corbus Pharmaceuticals announced the expansion of its portfolio into immuno-oncology through licensing deals with the University of California San Francisco and Panorama Research Inc for two new monoclonal antibodies (mAbs).

Licensing 52

Licensing Licensing Antibody Research 52

The Pharma Data

JANUARY 26, 2021

In what looks like a breakthrough for COVID-19 treatments, Regeneron’s monoclonal antibody cocktail REGEN-COV (casirivimab and imdevimab) cut infection rates in half and provided full protection against symptomatic COVID-19, according to interim results from a phase 3 trial evaluating the treatment as a passive vaccine.

Antibody 52

Antibody Vaccination Vaccine Trials 52

Drug Discovery World

MAY 25, 2023

Following the Scottish Research and Drug Development Forum meeting, DDW’s Diana Spencer provides a snapshot of drug discovery in Scotland. Introduction to the CRUK Beatson Institute The first speaker was Professor Owen Sansom, Director of the Cancer Research UK Beatson Institute, who gave two presentations.

Research 52

Research Drugs In-Vitro Insulin 52

Pharmaceutical Technology

JANUARY 8, 2023

In 2023, the pharmaceutical industry will mark 20 years since Xolair, an anti-IgE antibody, became the first biologic approved to treat asthma. Since then, the US FDA, EMA, and other agencies have approved several biologic antibodies targeting the inflammatory cytokines IL-4, IL-13, IL-5, and others for asthma.

Antibody 298

Antibody Trials Clinical Trials Clinical Trials 298

Pharmaceutical Technology

AUGUST 16, 2022

Of this amount, Horizon plans to recognise research and development (R&D) costs of nearly $32.5m antibody, ADX-914 re-regulates adaptive immune function by hindering IL-7 and TSLP-facilitated signalling. Q32 is entitled to get $55m as initial consideration and staged development funding during the option period.

Development 130

Development Clinical Trials Clinical Trials FDA Approval 130

XTalks

APRIL 15, 2021

Treatment for this specific type of blood clot is different from the treatment that might typically be administered, said Peter Marks, MD, PhD, Director, FDA Center for Biologics Evaluation and Research. He explained that usually an anticoagulant drug called heparin is used to treat blood clots.

Vaccination 98

Vaccination Vaccine Regulation Drugs 98

Advarra

JANUARY 11, 2024

The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. While mRNA usage has played several roles in clinical research , oncology researchers in particular are eager to explore the possibilities of mRNA-based cancer vaccines.

Vaccination 52

Vaccination Vaccine Protein Antibody 52

XTalks

NOVEMBER 26, 2020

In addition to innovative new antibody drugs and mRNA vaccines, researchers have found that the sleep-regulating hormone melatonin may also offer protection against COVID-19. Melatonin, which regulates the body’s circadian rhythm and sleep-wake cycle, is also available in pill form for use as a sleep aid.

Research 98

Research Hormones Protein Regulation 98

The Pharma Data

JANUARY 12, 2021

LONDON, UK / ACCESSWIRE / January 13, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has successfully completed the development of its CDX antibody with a leading global pharmaceutical company (“GlobalCo”).

Antibody 40

Antibody Development Licensing Licensing 40

Pharmaceutical Technology

OCTOBER 25, 2022

There are options in the future to possibly apply the worldwide research and development (R&D), manufacturing and marketing expertise of Astellas in gene therapy to AAV gene therapy development programmes of Taysha for genetic ailments of the central nervous system (CNS).

Gene Therapy 264

Gene Therapy Gene Development Genetics 264

The Pharma Data

SEPTEMBER 17, 2020

17, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly ‘s potential COVID-19 therapies. Lilly ‘s chief scientific officer and president of Lilly Research Laboratories.

Antibody 52

Antibody Manufacturing Production Sales 52

The Pharma Data

MARCH 25, 2021

today announced primary results from the Phase 2/3 RELATIVITY-047 (CA224-047) trial evaluating the fixed-dose combination of relatlimab, an anti-LAG-3 antibody, and Opdivo (nivolumab) versus Opdivo alone in patients with previously untreated metastatic or unresectable melanoma.

Antibody 52

Antibody Trials Clinical Trials Clinical Trials 52

STAT News

NOVEMBER 1, 2022

The company said that it plans to file the data on the vaccine with regulators by the end of the year and that it expects an eight-month review. By giving the vaccine during pregnancy, researchers hope antibodies generated by mothers would be transferred to their babies. RSV is a common cause of illness and infection in infants.

Vaccination 98

Vaccination Vaccine Antibody Regulation 98

STAT News

NOVEMBER 28, 2022

… A 65-year-old woman who was receiving a promising experimental treatment to slow the cognitive decline caused by her early Alzheimer’s disease recently died from a massive brain hemorrhage that some researchers link to the drug , Science reports. STAT reported on another such case last month.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Drugs 98

The Pharma Data

MARCH 22, 2021

Investigational antibody cocktail of casirivimab and imdevimab also significantly shortened the duration of symptoms by four days. The combination of casirivimab and imdevimab is the only monoclonal antibody treatment to retain potency against key emerging variants, based on the recently updated EUA guidance from the U.S.

Antibody 52

Antibody Trials Clinical Trials Clinical Trials 52

Pharmaceutical Technology

MARCH 10, 2023

Pharmaceutical and biotechnology industries widely use freeze-drying systems to protect vaccines, antibodies, antibiotics such as penicillin, blood plasma, proteins, enzymes, hormones, viruses, and bacteria from heat and minimise their biological activity. The process eliminates the disadvantages of conventional drying methods or freezing.

Manufacturing 147

Manufacturing Production Containment Antibody 147

The Pharma Data

DECEMBER 20, 2020

In a study published in the journal Nature Medicine , the Oxford researchers revealed that results from phase 1/2 trials showed that two full doses of the vaccine induced a stronger antibody response than one full dose and one-half dose. Efficacy was not measured in the phase 1/2 trials.

Antibody 52

Antibody Vaccination Vaccine Trials 52

Drug Discovery World

MARCH 31, 2023

As March draws to a close, this week’s key announcements have demonstrated the breadth of international approaches to tackling cancer, with vaccines, proenzymes, immunotherapies and antibody-based treatments all currently under investigation around the world.

Drugs 52

Drugs Antibody Vaccination Vaccine 52

The Pharma Data

AUGUST 18, 2020

REGN-COV2 is Regeneron’s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection. Regeneron has progressed the REGN-COV2 research and development program at record speed and worked tirelessly to maximize our in-house manufacturing capacity,” said Leonard S.

Antibody 52

Antibody Clinical Trials Clinical Trials Manufacturing 52

Pharmaceutical Technology

MARCH 9, 2023

In-vitro T-cell activation is a key innovation area in immuno-oncology T cells can be activated and differentiated in vitro by crosslinking the TCR with CD3 antibodies and PMA treatment. Activation of T-cell proliferation specifically in a tumour is crucial for reducing the autoimmune side effects of antitumour immunotherapy.

In-Vitro 130

In-Vitro Gene Editing Medicine Licensing 130

Drug Discovery World

APRIL 26, 2023

Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated in a preclinical study a potential new therapeutic approach to treating the most common form of lung cancer. During tumour progression, the researchers found that bone marrow macrophages act to suppress the recruitment and activation of natural killer cells.

Antibody 52

Antibody Research Clinical Development Regulation 52

Drug Discovery World

MARCH 26, 2024

For example, progress made in developing gene mutant-specific inhibitors, antibody-drug conjugates (ADC), or cellular therapies. We were there to present the latest findings from our research. MT: What’s next for STORM’s research? MT: What data did you present at the conference?

RNA 62

RNA In-Vivo In-Vitro DNA 62

Camargo

DECEMBER 13, 2021

Both the FDA’s Center for Drug Evaluation and Research (CDER) and its Center for Biologics Evaluation and Research (CBER) have regulatory responsibility for therapeutic biological products, which are subject to both the Federal Food, Drug and Cosmetic (FD & C) Act and the Public Health Service (PHS) Act. BLA process (CBER).

Development 161

Development Production Immune Response Licensing 161

BioPharma Reporter

JULY 25, 2023

ImmunoGen, a biotech company focused on the development of antibody-drug conjugate (ADC) technology to treat cancer, has announced a multi-target license and option agreement to research novel, first-in-class ADCs with ImmunoBiochem, a biopharma firm developing novel biological therapeutics.

Development 52

Development Licensing Licensing Antibody 52

Drug Discovery World

FEBRUARY 12, 2024

In the upcoming year, we will see the expansion of new, more complex markets and updated requirements from regulators. The challenge is harnessing the power of AI within a highly regulated industry. Developability prediction is often used in antibody development to reduce wet lab experiments and accelerate the drug discovery process.

Genome 139

Genome Genomics Life Science Gene Therapy 139

pharmaphorum

AUGUST 15, 2022

The new version – dubbed Spikevax Bivalent Original/Omicron – has been given conditional authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) based on phase 2/3 trial data, which showed it was better at stimulating neutralising antibodies against BA.1 1 candidate to regulators in Europe last month.

Vaccination 111

Vaccination Vaccine Antibody Regulation 111

Pharmaceutical Technology

DECEMBER 9, 2022

M&A – Commended PRODUCT LAUNCHES – Commended RESEARCH AND DEVELOPMENT – Commende d. Solvias is a Swiss-based pharmaceutical company focused on contract research, development and manufacturing. Pharmaceutical Technology Excellence Rankings – The Verdict.

Development 130

Development Manufacturing Production Vaccination 130

Pharmaceutical Technology

JUNE 4, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Genetics 130

Genetics Gene Expression DNA Antibody 130

The Pharma Data

NOVEMBER 1, 2020

Drug Industry Daily (DID) the premier online resource for savvy pharmaceutical professionals whose jobs depend on accurate knowledge about the daily activities of Congress, the FDA, other key regulators … and what their competitors are up to.

Antibody 52

Antibody Compliance Trials Regulation 52

The Pharma Data

JANUARY 24, 2021

Although this represents a doubling in comparison to an initial report following the first wave in May and June, the overall seroprevalence – the number of people with antibodies, which suggests a previous COVID-19 infection – remains very low and Canada remains a long way from herd immunity,” says CITF Executive Director Tim Evans.

Antibody 52

Antibody Vaccination Vaccine Regulation 52

pharmaphorum

APRIL 7, 2021

billion DKK ($672 million) from AbbVie after the companies struck an R&D deal to research epcoritamab, a bispecific antibody targeting CD3 and CD20 that the biotech developed in-house. Genmab has four technology platforms to draw from, with the most established being bispecific antibodies which target two receptors at once.

Antibody 91

Antibody Life Science Development Regulation 91